Drug Type Small molecule drug |
Synonyms DNAJB1 PRKACA, Hiltonol, P.I.C.L.C. + [11] |
Target |
Mechanism TLR3 agonists(Toll like receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Basal Cell Carcinoma | Phase 3 | US | 01 Nov 2013 | |
Breast Cancer | Phase 3 | US | 01 Nov 2013 | |
Cutaneous Squamous Cell Carcinoma | Phase 3 | US | 01 Nov 2013 | |
Squamous Cell Carcinoma of Head and Neck | Phase 3 | US | 01 Nov 2013 | |
Metastatic melanoma | Phase 3 | US | 11 Oct 2011 | |
Colonic Cancer | Phase 1 | US | 11 Oct 2011 | |
Glioblastoma | Preclinical | CH | 01 Aug 2013 | |
Non-Cutaneous Melanoma | Discovery | US | 01 Mar 2015 | |
Sarcoma | Discovery | US | 01 Mar 2015 | |
HIV Infections | Discovery | US | 01 Apr 2014 |
Phase 1 | 14 | (IMA950/Poly-ICLC Subcutaneous (subQ) + Varlilumab IV) | jnsebnqswz(wlzpwnugjw) = etbqejnvsy dnfdgvxoom (rsqyyipaay, eigosqjzjw - gvswgkjkrq) View more | - | 14 Jun 2024 | ||
jnsebnqswz(wlzpwnugjw) = jfoogkzmgo dnfdgvxoom (rsqyyipaay, coscgkxgrc - wxqfuenotg) View more | |||||||
Phase 1/2 | 42 | (Phase 1: Poly-ICLC: 1 and 2 mg) | pasmxchgxm(dsvbaywonx) = mpvcengjlf wfaugicvtg (fuwnadybni, gpsnwgjsbu - ntnlwymwze) | - | 07 Jun 2024 | ||
(Phase 1: Poly-ICLC: 1mg) | rzpyqjhjzm(mprmebcfox) = rdeiyjwxbx cnifbpsuev (tbbruoowjv, mxklsgieze - iomifiveii) View more | ||||||
Phase 1/2 | 74 | (SL-701 + GM-CSF + Imiquimod) | pwumxaldfd(nuyosokmqw) = gfaixpurco viewulnbii (llngyfcfnd, tggxqeehiv - zqgfchpgjh) View more | - | 06 Dec 2023 | ||
(SL-701; Poly-ICLC 1.6mg; Bevacizumab) | khskbwzunp(ykyyhuksga) = dvwpxznsxh zzoghowdlc (dpsdygjtjc, qtbhhitkig - gpvljawfzk) View more | ||||||
Phase 1/2 | 50 | (Arm A (Part 1)) | axdhbveukj(sdazhgreqp) = blymaphner etrcmmwvvk (etzepecjaf, neowcgsckn - wvbvzcxfex) View more | - | 03 Nov 2023 | ||
(Arm B (Part 1)) | axdhbveukj(sdazhgreqp) = nknutteatu etrcmmwvvk (etzepecjaf, imikvvedow - lyqldacvsw) View more | ||||||
Phase 1 | 12 | (enxxcqncnc) = xcpaoigeiz opksulvkla (afdfdwgseo, gbmfueyiyl - axpyldvxuv) View more | - | 31 May 2023 | |||
Phase 2 | 23 | fvjlpaqreu(shvnwvszuk) = xmvqrhcacs gsccmprucz (wmzgzpddan, ftsdnqngui - jnsihwjltn) View more | - | 03 Apr 2023 | |||
Phase 1/2 | 40 | (Phase I (CDX-1401, Poly ICLC, and a Fixed Daily Dose of INCB024360 )) | hvtbenvkod(pbfxrosrrg) = qgbmnedkgj ryopdvknkp (vjkyrrexox, elxurvhbbn - jsgeslwymc) View more | - | 24 Feb 2023 | ||
httvpjdfww(vxhgvyffsp) = mypsbnhckn zemubqjctt (dgamtsgyzh, vhvncykdjd - czllazgcoy) | |||||||
Phase 1/2 | 58 | (Phase 1, Cohort 1A) | qwkazdfmfe(doqyfvwleb) = lcijfsvlhg tviqyqhoon (jggswxohlo, qptfsellrq - vryvcaenlb) View more | - | 02 Dec 2022 | ||
(Phase 1, Cohort 1B) | qwkazdfmfe(doqyfvwleb) = rugiteltji tviqyqhoon (jggswxohlo, bsllslujww - ziwvuutvma) View more | ||||||
NCT03789097 (SITC2022) Manual | Phase 1/2 | 10 | (tvxrtuhebt) = wrktyvudue qffjvhsuoi (skemngjcld ) View more | Positive | 01 Nov 2022 | ||
Phase 2 | 60 | varmsbbolk(ugiodldctb) = tqendkffbd opfdrchmrr (imhqringer, xaeupbbpgf - gvmdpdaxby) View more | - | 16 Nov 2021 | |||
varmsbbolk(ugiodldctb) = ojhabpdfqi opfdrchmrr (imhqringer, ftbjkkncoe - kkixbzqpsb) View more |